Drug Trial Radar · NCT06728865
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Sep 4, 2024
Primary completion
Feb 1, 2028
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- Li-kun ChenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of Befotertinib combined with Bevacizumab as a first-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) accompanied by brain or leptomeningeal metastases. It is a single-arm, open-label, prospective Phase II clinical trial aiming to explore the potential benefits of this combination therapy in improving intracranial progression-free survival (iPFS) and overall survival (OS). Patients will receive Befotertinib daily and Bevacizumab every three weeks until disease progression, intolerable toxicity, or withdrawal of consent. The study seeks to address the unmet need for effective treatments in this challenging patient population.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- EGFR Mutation-Positive Lung Cancer
- Brain Metastases
- Leptomeningeal Metastases
- Intracranial Tumor Progression
Interventions
The treatment regimen is Befotertinib combined with Bevacizumab.Drug
The treatment regimen is Befotertinib combined with Bevacizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-Month Intracranial Progression-Free Survival Rate Assessed by RECIST 1.1 in Patients with EGFR-Mutant NSCLC and Brain MetastasesTime frame: 12 months from the initiation of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.